Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Numinus Wellness Focused on Boosting Profitability and Expanding Community Support (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ovid Therapeutics Inc OVID

Healthcare Biotechnology
Ovid Therapeutics Inc. is a biopharmaceutical company. The Company is focused on improving the lives of people affected by certain epilepsies and brain conditions with seizure symptoms. It is engaged in advancing a pipeline of novel, targeted small molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of seizures and other... see more

Recent & Breaking News (NDAQ:OVID)

Takeda and Ovid Therapeutics Expand Clinical Program for TAK-935/OV935 with Three New Studies in Rare Developmental and Epileptic Encephalopathies (DEE)

GlobeNewswire July 18, 2018

Ovid Therapeutics Announces Presentations Related to OV101 Fragile X Syndrome Program at the 16th National Fragile X Foundation (NFXF) International Conference

GlobeNewswire July 11, 2018

Ovid Therapeutics Announces Initiation of Phase 2 ROCKET Clinical Trial to Evaluate OV101 in Fragile X Syndrome

GlobeNewswire July 11, 2018

Ovid Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference on June 8, 2018

GlobeNewswire May 30, 2018

Ovid Therapeutics Announces Two Oral Presentations at the 14th Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIV)

GlobeNewswire May 9, 2018

Ovid Therapeutics Reports First Quarter 2018 Financial Results and Corporate Progress

GlobeNewswire May 8, 2018

Ovid Therapeutics to Present at Deutsche Bank’s 43rd Annual Health Care Conference on May 9, 2018

GlobeNewswire May 2, 2018

Ovid Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Corporate Progress

GlobeNewswire March 29, 2018

Ovid Therapeutics to Host Fourth Quarter and Full Year 2017 Financial Results Conference Call on Thursday, March 29, 2018

GlobeNewswire March 15, 2018

Ovid Therapeutics Announces OV101 Granted Fast Track Designation by U.S. FDA for Treatment of Fragile X Syndrome

GlobeNewswire March 15, 2018

Ovid Therapeutics to Present at Two Upcoming Investor Conferences

GlobeNewswire March 5, 2018

Ovid Therapeutics Announces Multiple Poster Presentations of OV101 and TAK-935/OV935 at the American Academy of Neurology 70th Annual Meeting

GlobeNewswire March 1, 2018

Ovid Therapeutics to Present at the RBC Capital Markets 2018 Global Healthcare Conference

GlobeNewswire February 15, 2018

Ovid Therapeutics Announces TAK-935/OV935 Granted Orphan Drug Designation by U.S. FDA for Treatment of Lennox-Gastaut Syndrome

GlobeNewswire December 20, 2017

Ovid Therapeutics Announces OV101 Granted Fast Track Designation by U.S. FDA for Treatment of Angelman Syndrome

GlobeNewswire December 19, 2017

Ovid Therapeutics Announces TAK-935/OV935 Has Received Orphan Drug Designation from U.S. FDA for Treatment of Dravet Syndrome

GlobeNewswire December 5, 2017

Ovid Therapeutics Presents New Data Demonstrating Potential of TAK-935/OV935 as a Novel Treatment for Developmental and Epileptic Encephalopathies at the American Epilepsy Society (AES) Annual Meeting

GlobeNewswire December 3, 2017

Ovid Therapeutics Announces OV101 Shows Comparable PK Profile in Phase 1 Study of Adolescent Patients and Amends Phase 2 STARS Clinical Trial Protocol to Include Adolescents

GlobeNewswire November 28, 2017

Ovid Therapeutics Announces Five Poster Presentations on TAK-935/OV935 at the American Epilepsy Society 71st Annual Meeting

GlobeNewswire November 21, 2017

Ovid Therapeutics to Participate in Two Upcoming Investor Conferences

GlobeNewswire November 20, 2017